Genmab A/S Sponsored ADR (GMAB) vs Roivant Sciences Ltd. (ROIV)
- Genmab A/S Sponsored ADR GMAB 37.00 −2.17%
- Roivant Sciences Ltd. ROIV 33.53 −1.50%
Genmab A/S Sponsored ADR and Roivant Sciences Ltd. are both Biotechnology companies. Genmab A/S Sponsored ADR and Roivant Sciences Ltd. are of similar size ($24.6B and $22.6B). Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Genmab A/S Sponsored ADR trades at 29.1×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 22.3% against −67.6%. Genmab A/S Sponsored ADR has the higher net margin (19.1% vs −3,535.0%) and the higher return on invested capital (6.99% vs −34.5%). Across the 19 metrics below, Genmab A/S Sponsored ADR leads on 16 and Roivant Sciences Ltd. on 3.
Valuation
Profitability
| Metric | GMAB | ROIV | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.03% | 81.21% | 65.16% |
| Operating margin | 25.95% | (7,914.75%) | 0.00% |
| Net margin | 19.08% | (3,534.96%) | 0.00% |
| Free cash flow margin | (153.64%) | (10,901.00%) | 0.00% |
| Return on equity | 14.00% | (5.47%) | (56.36%) |
| Return on assets | 8.30% | (5.15%) | (48.04%) |
| Return on invested capital | 6.99% | (34.51%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack